Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
KPVI,
CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…